January 7, 2025 Kigali, Rwanda and San Francisco, USA

Bio Usawa, Inc (BUI Website) is pleased to announce that its Co-Founder and CEO, Menghis Bairu, MD, joined the Board of Directors of the #Society for Equity Neuroscience (SEQUINS). The Society is the central and unifying global organization for Equity Neuroscience, which is the study of how the brain is affected by #health inequities and diverse barriers that can lead to suboptimal functioning of the nervous system.

Dr. Bairu brings with him a storied history in the fields of neurodegenerative diseases, as well as a long-standing commitment to driving health equity across the globe, especially in low-middle income countries (LMICs). His deep understanding of the pathophysiology of neurodegenerative disorders has driven innovative therapeutic strategies, significantly advancing treatment protocols and clinical trial methodologies for these complex conditions. His years of experience in the biotechnology industry will further augment SEQUINS’ impressive efforts to address the Brain Health Inequality that the world now faces, with a focus on marginalized communities where the prevalence of neurodegenerative diseases is expected to increase dramatically as populations age. 

Please join us in congratulating Dr. Bairu on his new Directorship.

About The Society for Equity Neuroscience (SEQUINS)

The Society for Equity Neuroscience (SEQUINS) founded in 2024 aims to enhance brain health around the world by improving equitable nervous system care and outcomes through research.

Neurological disorders disproportionately affect certain racial and ethnic communities (e.g., Black, Indigenous, and people of color), those in lower socioeconomic groups, individuals living in underserved geographies including rural areas and low-income countries, and other marginalized populations. SEQUINS, founded in 2024, aims to enhance brain health around the world by improving equitable nervous system care and outcomes through research.

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our Company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.